199 related articles for article (PubMed ID: 36933492)
1. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.
Zhang L; Feng J; Kuang T; Chai D; Qiu Z; Deng W; Dong K; Zhao K; Wang W
Int Immunopharmacol; 2023 May; 118():110019. PubMed ID: 36933492
[TBL] [Abstract][Full Text] [Related]
2. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
3. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis.
Tian BW; Yan LJ; Ding ZN; Liu H; Meng GX; Xue JS; Han CL; Dong ZR; Hong JG; Chen ZQ; Wang DX; Li T
Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):73-83. PubMed ID: 36476076
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
Wang R; Lin N; Mao B; Wu Q
J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
[TBL] [Abstract][Full Text] [Related]
5. Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients.
Sun X; Mei J; Lin W; Yang Z; Peng W; Chen J; Zhang Y; Xu L; Chen M
BMC Cancer; 2021 Jul; 21(1):775. PubMed ID: 34218801
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors.
Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963
[TBL] [Abstract][Full Text] [Related]
8. Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis.
Tian BW; Yan LJ; Ding ZN; Liu H; Han CL; Meng GX; Xue JS; Dong ZR; Yan YC; Hong JG; Chen ZQ; Wang DX; Li T
Int Immunopharmacol; 2023 Jan; 114():109519. PubMed ID: 36459922
[TBL] [Abstract][Full Text] [Related]
9. Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis.
Xu H; Cao D; Zheng Y; Zhou D; Chen X; Lei J; Ge W; Xu X
Int Immunopharmacol; 2021 Nov; 100():108135. PubMed ID: 34530205
[TBL] [Abstract][Full Text] [Related]
10. The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors.
Zhang L; Chen C; Chai D; Li C; Guan Y; Liu L; Kuang T; Deng W; Wang W
Front Immunol; 2022; 13():956533. PubMed ID: 36059512
[TBL] [Abstract][Full Text] [Related]
11. Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
Xu H; Cao D; Zhou D; Zhao N; Tang X; Shelat VG; Samant H; Satapathy SK; Tustumi F; Aprile G; He A; Xu X; Ge W
BMC Cancer; 2023 Oct; 23(1):1006. PubMed ID: 37858207
[TBL] [Abstract][Full Text] [Related]
12. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of prognostic risk prediction models for hepatocellular carcinoma patients treated with immune checkpoint inhibitors based on a systematic review and meta-analysis of 47 cohorts.
Ma D; Liu M; Zhai X; Li X; Jin B; Liu Y
Front Immunol; 2023; 14():1215745. PubMed ID: 37520554
[TBL] [Abstract][Full Text] [Related]
14. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma.
Shao YY; Liu TH; Hsu C; Lu LC; Shen YC; Lin ZZ; Cheng AL; Hsu CH
Liver Int; 2019 Nov; 39(11):2184-2189. PubMed ID: 31400295
[TBL] [Abstract][Full Text] [Related]
15. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
Front Immunol; 2021; 12():794099. PubMed ID: 34950153
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Liu Y; Pan J; Gao F; Xu W; Li H; Qi X
Adv Ther; 2023 Feb; 40(2):521-549. PubMed ID: 36399316
[TBL] [Abstract][Full Text] [Related]
17. Combination of neutrophil/lymphocyte ratio and albumin/bilirubin grade as a prognostic predictor for hepatocellular carcinoma patients undergoing curative hepatectomy.
Luo H; Huang C; Meng M; Zhang M; Li Z; Huang J
BMC Gastroenterol; 2023 May; 23(1):162. PubMed ID: 37208618
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
[TBL] [Abstract][Full Text] [Related]
19. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.
Liu N; Mao J; Tao P; Chi H; Jia W; Dong C
Medicine (Baltimore); 2022 Jan; 101(3):e28617. PubMed ID: 35060536
[TBL] [Abstract][Full Text] [Related]
20. Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients.
Zhang J; Wang L; Zhang S; Cao R; Zhao Y; Zhao Y; Song Y; Guo Z
BMC Cancer; 2024 Feb; 24(1):266. PubMed ID: 38408930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
